Atlas Trials

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

Clinical trial NCT06496373 · RECRUITING

Trial details

NCT number
NCT06496373
Sponsor
Ruijin Hospital
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Pancreatic Cancer ResectableChemotherapy-intolerant
Start date
2024-07-16
Primary completion
2026-06-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.